GENSIA PROTARA THIRD PHASE III HALTED BY OUTSIDE MONITORING COMMITTEE
Executive Summary
GENSIA PROTARA THIRD PHASE III HALTED BY OUTSIDE MONITORING COMMITTEE because an interim analysis of data collected met a prespecified stopping point for the trial, the San Diego biotech firm reported Aug. 12. Gensia, however, is still blinded to the results and does not know whether the independent safety and data monitoring committee decided to halt the trial because of positive or negative efficacy results of Protara (acadesine, formerly Arasine) in patients undergoing coronary artery bypass surgery. The committee did tell the firm that the trial was not halted for safety reasons.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth